RECOMBINANT ALPHA-2 INTERFERON THERAPY FOR KAPOSIS SARCOMA ASSOCIATED WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME
RECOMBINANT ALPHA-2 INTERFERON THERAPY FOR KAPOSIS SARCOMA ASSOCIATED WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME
复制标题
DOI：
10.7326/0003-4819-100-5-671
复制
发表时间：
1984-01-01
影响因子：
39.2
通讯作者：
VOLBERDING, PA
中科院分区：
文献类型：
--
作者：
GROOPMAN, JE;GOTTLIEB, MS;VOLBERDING, PA
在一项随机前瞻性研究中，重组α- 2干扰素用于治疗与获得性免疫缺陷综合征相关的卡波西肉瘤。高剂量L50 ×106 U/m2体表面积，i. v.）或低剂量（1 × 10 - 4）。106 U/m2，s.c.）重组α- 20例患者用干扰素2治疗，每周5天，每2周1次，共4个周期。治疗的主观耐受性良好，在两个剂量水平下仅引起轻度血液学和肝脏毒性。治疗期间或治疗后，免疫学变量未观察到一致或持续的变化。6例Kaposis肉瘤患者（4例高剂量组和2例低剂量组）对治疗有客观反应（完全或部分）。然而，治疗似乎没有根除巨细胞病毒携带或预防与巨细胞病毒相关的机会性感染。
In a randomized prospective study the toxicity and efficacy of recombinant .alpha.-2 interferon was tested in the treatment of Kaposi''s sarcoma associated with the acquired immunodeficiency syndrome. High doses L50 .times. 106 U/m2 body surface area, i.v.) or low doses (1 .times. 106 U/m2, s.c.) of recombinant .alpha.-2 interferon were administered to 20 patients for 5 days/wk, every other week, for 4 treatment cycles. Therapy was well tolerated subjectively and caused only mild hematologic and hepatic toxicity at both dose levels. No consistent or sustained changes were seen in immunologic variables during or after treatment. Six patients with Kaposi''s sarcoma, 4 at high dose and 2 at low dose, had objective responses (complete or partial) to treatment. However, therapy did not appear to eradicate cytomegalovirus carriage or prevent opportunistic infections related to cytomegalovirus.